Cargando…

Prolargin and matrix metalloproteinase‐2 in heart failure after heart transplantation and their association with haemodynamics

AIMS: Remodelling of the extracellular matrix (ECM) is a key mechanism involved in the development and progression of heart failure (HF) but also functional in associated pulmonary hypertension (PH). Our aim was to identify plasma ECM proteins associated to end‐stage HF and secondary PH in relation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmed, Abdulla, Ahmed, Salaheldin, Arvidsson, Mattias, Bouzina, Habib, Lundgren, Jakob, Rådegran, Göran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083509/ https://www.ncbi.nlm.nih.gov/pubmed/31858729 http://dx.doi.org/10.1002/ehf2.12560

Ejemplares similares

Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics
por: Ahmed, Abdulla, et al.
Publicado: (2020)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021)

Elevated plasma tyrosine kinases VEGF-D and HER4 in heart failure patients decrease after heart transplantation in association with improved haemodynamics
por: Ahmed, Salaheldin, et al.
Publicado: (2020)

Elevated plasma endocan and BOC in heart failure patients decrease after heart transplantation in association with improved hemodynamics
por: Ahmed, Salaheldin, et al.
Publicado: (2020)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)

Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019)

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2022)

Elevated plasma WIF‐1 levels are associated with worse prognosis in heart failure with pulmonary hypertension
por: Kania, Kriss, et al.
Publicado: (2022)

Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension
por: Ahmed, Salaheldin, et al.
Publicado: (2021)

Plasma Biomarkers for Clinical Assessment of Bone Mineral Density in Heart Transplanted Patients—A Single-Center Study at Skåne University Hospital in Lund
por: Löfdahl, Eveline, et al.
Publicado: (2022)

Plasma tumour necrosis factor‐alpha‐related proteins in prognosis of heart failure with pulmonary hypertension
por: Engel Sällberg, Adam, et al.
Publicado: (2023)

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2023)

Hemodynamic Characteristics Including Pulmonary Hypertension at Rest and During Exercise Before and After Heart Transplantation
por: Lundgren, Jakob, et al.
Publicado: (2015)

Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2018)

Association between central haemodynamics and renal function in advanced heart failure: a nationwide study from Sweden
por: Bobbio, Emanuele, et al.
Publicado: (2022)

Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
por: Ahmed, Abdulla, et al.
Publicado: (2021)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
por: Bergh, Niklas, et al.
Publicado: (2020)

Deranged Lung Perfusion Pattern in Patients With Heart Failure Normalizes After Heart Transplantation
por: Al-Mashat, Mariam, et al.
Publicado: (2020)

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2019)

Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator
por: Ahmed, Abdulla, et al.
Publicado: (2023)

A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis
por: Sinkeviciute, Dovile, et al.
Publicado: (2020)

Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure
por: Gonçalves, Pricila Rodrigues, et al.
Publicado: (2022)

Matrix Metalloproteinases and Heart Transplantation—A Pathophysiological and Clinical View
por: Patrichi, Gabriela, et al.
Publicado: (2023)

Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure
por: Morishita, Tetsuji, et al.
Publicado: (2017)

Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute Decompensated Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2015)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Haemodynamic determinants of quality of life in chronic heart failure
por: Fatrin, Serlie, et al.
Publicado: (2022)

Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization
por: Jögi, Jonas, et al.
Publicado: (2018)

Genomic ancestry as a predictor of haemodynamic profile in heart failure
por: Bernardez-Pereira, Sabrina, et al.
Publicado: (2016)

Haemodynamic effects of levosimendan in advanced but stable chronic heart failure
por: Najjar, Emil, et al.
Publicado: (2018)

Abnormal haemodynamic postural response in patients with chronic heart failure
por: Bronzwaer, Anne‐Sophie G.T., et al.
Publicado: (2017)

Haemodynamic Effects of Anaemia in Patients with Acute Decompensated Heart Failure
por: Krzesiński, Paweł, et al.
Publicado: (2020)

Relationship between haemodynamic indicators and haemogram in patients with heart failure
por: Oh, Takuya, et al.
Publicado: (2022)

Haemodynamic effects of percutaneous mitral valve edge‐to‐edge repair in patients with end‐stage heart failure awaiting heart transplantation
por: Geis, Nicolas A., et al.
Publicado: (2018)

Ambulatory haemodynamic‐guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort
por: Dauw, Jeroen, et al.
Publicado: (2022)

Haemodynamic monitoring in acute heart failure – what you need to know
por: Jasińska-Gniadzik, Karolina, et al.
Publicado: (2022)

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
por: Fröhlich, Hanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b2cm3j1c37lqqbdgggs2qkug52